Boudjadi Salah

BOUDJADI Salah

Medical Doctor, Ph.D. in Anatomic and Cell Biology Staff Scientist - Bladder Cancer Section, National Cancer Institute (NCI), United States

Origins & Education

Dr. Salah Boudjadi was born in 1978 in Skikda, Algeria. He completed his secondary education at Sediki Yahya High School before pursuing his medical training at Badji Mokhtar University in Annaba, where he earned his Medical Degree from the Faculty of Medicine. Driven by a passion for biomedical research, he subsequently obtained a Ph.D. in Anatomic and Cell Biology, a specialization that deepened his understanding of cellular and molecular disease mechanisms.

His areas of expertise span a broad spectrum including Biology, Biochemistry, Agronomy, Geology, Medicine, Pharmacy, Veterinary Sciences, and Sports, reflecting his exceptional multidisciplinary training.

Scientific Career

Dr. Boudjadi's career spans over 15 years of research dedicated to understanding key gene expression alterations related to cancer progression. His professional trajectory has been defined by a deep interest in translational oncology, particularly in understanding cancer resistance mechanisms and identifying new therapeutic strategies.

During his pathology residency in France, he worked on diagnosing diverse human pathologies, including cancer. This interaction with different diseases at the morphological level increased his curiosity about the molecular mechanisms of cancers and raised questions about how to effectively treat this devastating disease. After completing his research training in Canada, he focused on studying gene expression control in human intestinal cells, particularly in colorectal cancer.

At the National Cancer Institute (NCI), as a Staff Scientist in the Bladder Cancer Section of the Genitourinary Malignancies Branch, he currently leads a research laboratory developing new projects focused on developing in vivo models to study metastatic bladder cancer and its resistance to different therapies, including antibody-drug conjugates (ADCs).

His current research also focuses on discovering new therapeutic targets for rare genitourinary tumors, which account for about 20% of all malignancies when considered cumulatively, with an increasing incidence of 0.5% each year. These tumors are generally aggressive with high relapse rates and resistance to conventional therapies.

Distinctions & Recognition

Impact & Influence

Dr. Boudjadi has successfully published his findings in recognized scientific journals and developed a methodology for identifying transcription factor-responsive elements in gene promoters. He has also collaborated on other research projects in cell biology and worked on developing screening tools for early colorectal cancer detection.

His major contributions include research on integrin α1β1 in colorectal cancer progression, transcriptional control of gene expression in cancer diseases, and the development of antibody-drug conjugate resistance models. His work aims to explore DNA changes, expression signatures, and pathway alterations to better understand the biology of these aggressive rare tumors and discover new oncogenic drivers and potential therapeutic targets.

He is currently working on developing and characterizing novel in vivo and in vitro models of ADC resistance using multidisciplinary approaches involving genomics, bioinformatics, cell culture, and animal models to determine the biological relevance of ADC resistance mechanisms.

For More Information